Screener / SEC EDGAR /CIK 0001420800 /10-K filed Feb 26, 2026, compared with Feb 26, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Devices

Enovis CORP ENOV

Compare with peers Embed
The 10-K against last year's

154 changes: 34 added, 26 removed, 90 reworded, 4 quiet changes

10-K Feb 26, 2026 vs Feb 26, 2025

10-K 0001420800-26-000012 (Feb 26, 2026) vs 10-K 0001420800-25-000009 (Feb 26, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

129 paragraphs · 4 new · 38 reworded · 7 gone · 10-K Feb 26, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 125 · 46% changed Every version of it
The loss of key leadership or the inability to attract, develop, engage, train, integrate, and retain qualified employees employees, could impair our ability to execute our business strategy and could have a material adverse effect on our ability to run our business. business, financial condition and results of operations.
Paragraph 110 · 35% changed Every version of it
We are subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”), the U.K. Bribery Act, and similar anti-bribery laws in other jurisdictions that generally prohibit companies and those acting on their behalf from authorizing, promising, offering or providing, directly or indirectly, improper payments or anything else of value to government officials to obtain or retain business or other commercial advantage, and the U.K. Bribery Act and other anti-bribery laws also prohibit similar conduct between private parties. The FCPA also imposes obligations on publicly traded U.S. corporations that are intended to prevent the diversion of corporate funds for improper payments and the establishment of “off the books” slush funds from which such payments can be made and to provide assurance that transactions are accurately recorded, lawful and in accordance with management’s authorization. Because of the predominance of government-sponsored health care systems around the world, many of our customer relationships outside of the United States are with government entities. As a result, interactions with those customers present compliance risk under the FCPA and other anti-bribery laws. In addition, anti-bribery laws can pose unique challenges for companies with foreign operations in countries where corruption is a recognized problem. While we believe we have implemented appropriate policies and procedures to mitigate risk of non-compliance with the FCPA and other applicable anti-bribery laws by the Company and persons or entities acting on our behalf, we cannot assure that such policies, procedures, and training will always protect us from violations by our employees, distributors or other agents. In addition, we may be exposed to liability due to pre-acquisition conduct of businesses or operations we acquire, as well as the conduct of their employees, distributors or other agents. Violations of anti-bribery laws, or allegations thereof, could disrupt our operations, distract management, and have a material adverse effect on our business, financial condition, results of operations and cash flows. We also could be subject to criminal and civil penalties, disgorgement, substantial expenditures related to remedial actions, and reputational harm.
Paragraph 8 · 35% changed Every version of it
Further, we are required to assess the effectiveness of the internal control over financial reporting for companies we acquire pursuant to the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”). We may elect the one year scope exception provided by the Exchange Act and the applicable SEC rules and regulations concerning business combinations as we did for the Lima acquisition, but we can not cannot avoid the requirements. In order to comply with the Sarbanes-Oxley Act, we will need to implement or enhance internal control over financial reporting at any company we acquire, and we may identify control deficiencies that require remediation as part of our evaluation and testing of internal controls. Companies we acquire may not have had previous public reporting obligations and therefore may not have instituted or evaluated internal controls in the context of the Sarbanes-Oxley Act. Any failure to implement and maintain effective internal control over financial reporting could result in material weaknesses or significant deficiencies in our internal controls, and could result in a material misstatement of our financial statements or otherwise cause us to fail to meet our financial reporting obligations, which could have an adverse effect on our results of operations, financial condition, and business.
Paragraph 29 · 33% changed Every version of it
The spread or fear of spread of contagious diseases, terrorist activity, man-made or natural disasters, actual or threatened war, political unrest, civil strife and other geopolitical uncertainty could have cause a similar effect on decline in the demand for our products, which may adversely affect our financial condition condition, growth strategy and operating performance. In addition, pandemics and public health emergencies, and government measures in response to such emergencies, have in the past and could in the future result in additional challenges for our business, including disruptions or delays to our growth strategy. supply chain and distribution channels, cost inflation, and healthcare provider staffing shortages. Any one or more of these events may reduce the overall demand for our products which could adversely affect our results of operations, financial condition, and business
Paragraph 49 · 32% changed Every version of it
Our products are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities, as discussed under “Regulatory Environment – Medical Device Regulation” in Part I, Item 1. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.
Paragraph 48 · 29% changed Every version of it
Our products are subject to rigorous regulation by the FDA and numerous other federal, state and foreign governmental authorities, as discussed under “Regulatory Environment – Medical Device Regulation” in Part I, Item 1. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all.
Paragraph 120 · 26% changed Every version of it
Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by geopolitical uncertainty, political instability, and conflicts, such as the ongoing conflict armed conflicts between Russia and Ukraine. Ukraine and in the Middle East.
Paragraph 102 · 26% changed Every version of it
Our information technology infrastructure and information are vulnerable to service interruptions, data corruption, cyber-based attacks, or network security breaches, which could result in the disruption of operations or the loss of data confidentiality. breaches.

MD&A

145 paragraphs · 30 new · 58 reworded · 19 gone · 10-K Feb 26, 2026 against Feb 26, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 57 · 49% changed
The increase in Net sales increased during 2023 Sales of $400.4 million for 2024 as compared to 2022 2023 was primarily attributable to an increase in sales from the Lima Acquisition and to a lesser extent the Novastep acquisition in our Recon segment. Additionally, Net Sales increased due to an the increase in sales from existing businesses across both of our segments and to segments, partially offset by a lesser extent sales decrease from acquired businesses the divestiture of a hosiery product line in Recon and favorable foreign currency translation. Recon sales increased by $94.9 million, or 17.7%, of which $76.7 million was due to significantly higher sales volumes than the prior year across all product lines driven by market outperformance and new product launches. our P&R sales increased $49.2 million, or 4.8%, of which $47.1 million was due to improved sales volumes and inflation-related pricing increases. Net sales from acquisitions increased during 2023 primarily due to the Novastep and 360 Med Care acquisitions in Recon that closed in 2023 and 2022, respectively. Lastly, the weakening of the U.S. dollar relative to other currencies, most notably the Swiss Franc and Euro, caused a $6.1 million favorable currency translation impact. segment.
Paragraph 81 · 49% changed
Net Selling, general and administrative expenses increased slightly as a percentage of net sales. Operating loss and Operating loss margin increased due to the Goodwill impairment charge of $387.8 million, offset by operating leverage with the aforementioned higher gross profit exceeding the aforementioned increase in Selling, general and administrative expenses. Adjusted EBITDA increased due to the increase in gross profit and improved mix of higher-margin product sales in P&R increased $21.2 million, or 2.0%, and Adjusted EBITDA margin decreased slightly compared with the prior year period, which was negatively impacted by a $11.1 million decrease from divesting a minor product line. Comparable Sales Growth for P&R was driven by approximately 3.0% organic growth period due to the timing of the aforementioned increased investment in volumes and partially offset by unfavorable foreign currency translation of 0.4%. Gross profit increased $10.9 million and Gross profit margin remained flat despite a lower mix of higher margin products sales. Selling, the business in selling, general and administrative expense decreased $10.5 million, primarily due to reduction of strategic transaction costs and EU MDR spending. Operating loss increased due to a Goodwill impairment charge the net impact of $315.0 million and charges from divesting a minor product line, partially offset by a Selling, general and administrative expense decrease and higher gross profit. Adjusted EBITDA and Adjusted EBITDA margin increased due to improved operating scale from lower overheads, partially offset by unfavorable foreign currency impacts in a primary manufacturing facility during the year ended December 31, 2024 compared to the prior year. new tariffs.
Paragraph 98 · 48% changed
On October 23, 2023 December 8, 2025, the Company entered into an amendment Amendment No. 3 to the Credit Agreement (the “Amendment”). “Third Amendment”). The Third Amendment provided for a new term increased the borrowing capacity under the Revolver to up to $1.1 billion and increased the loan commitment in under the aggregate amount of $400 million. The Term Loan Facility extended to $700 million. Pursuant to the Company under Third Amendment, the Amendment was funded on January 3, 2024, the date the Lima Acquisition was consummated. The Term Loan Facility requires quarterly principal repayments, which is $5 repayments of $8.75 million. The Third Amendment also extended the maturity date for all revolving loans and term loans under the Revolver and Term Loan Facility, respectively, to December 8, 2030. A portion of the incremental borrowings under the Term Loan Facility was used to repay approximately $335 million each quarter, of the outstanding principal balance under the Revolver. As of December 31, 2025, $157 million and matures $688 million was outstanding on April 4, 2027 (the “2024 the Revolver and Term Loan”). Loan respectively.
Paragraph 134 · 47% changed
A further sustained decline in our share price and market capitalization, future cash flows, end-markets and/or geographic markets could result in additional impairment charges that could materially affect our financial statements in any given year. Actual results could differ from our estimates and projections, which would also affect the assessment of impairment. As of December 31, 2025, including the charges from the year ended December 31, 2024, after recognition of the $645 million accumulated non-cash goodwill impairment charge, we have Goodwill of loss is $1.7 billion ($925 million for the Reconstructive reporting unit and $768 ($694.8 million for the Prevention and Recovery reporting unit) that is subject to at least annual review unit and $992.0 million for impairment. the Reconstructive reporting unit). See Note 9 “Goodwill and Intangible Assets” in the accompanying Notes to Consolidated Financial Statements for further information. the table summarizing the activity in Goodwill.
Paragraph 85 · 45% changed
Net sales increased in Recon by $101.4 million, or 10%, due to strong sales volumes and favorable currency translation of 1.8%. Gross profit increased $190.0 $118.9 million during 2024 in comparison to 2023 the year ended December 31, 2025 primarily due to a $179.1 million increase in Recon higher net sales, improved operating leverage and a $10.9 million increase in P&R. The Gross profit increase was attributable to increased sales from the Lima Acquisition, offset by an increase decrease of $51.6 $33.6 million in inventory fair value step-up amortization charges. Gross profit margin decreased by 200 basis points due to the aforementioned increase in inventory fair value step-up amortization charges.
Paragraph 86 · 44% changed
Selling, general and administrative expense increased $57.4 by $8.3 million during 2023 in comparison to 2022, over the same period primarily due to increased an increase in commissions driven by higher sales, sales and increases in existing business investments to support growth, spending on MDR and other costs, and cost inflation, partially nearly entirely offset by cost reduction initiatives and a net decrease in Strategic transactions Lima Acquisition integration costs. Research and development costs also expense increased compared to the prior year period, primarily period due to increased spend an increase in new product development projects and activities and spending within our recently acquired businesses in Recon, businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Amortization Purchase of acquired intangibles royalty interest increased over the same period as we completed strategic purchases to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements for a fixed price of $56.5 million, which will be paid over nine years. We accrued a liability and Depreciation and other amortization also increased compared to recognized a $45.8 million charge for the prior year period due to business acquisitions. net present value of the purchases.
Paragraph 63 · 44% changed
Selling, general and administrative expense increased $57.4 $42.8 million during 2023 2025 in comparison to 2022, 2024, primarily due to a $31.8 million increase in commissions on increased commissions sales and increased investment in the business in selling, general and administrative costs of $14.9 million, offset by a $17.9 million decrease in strategic transactions costs driven by higher sales, investments to support growth, spending on MDR and other costs, and cost inflation, partially offset by cost a reduction initiatives and a net decrease in Strategic transactions acquisition integration costs. Research and development costs also increased compared to the prior year period, primarily due to increased spend within recently acquired businesses in Recon, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Amortization of acquired intangibles and Depreciation and other amortization also increased compared to the prior year period due to business acquisitions.
Paragraph 27 · 43% changed
Adjusted EBITDA excludes from Net income (loss) from continuing operations the effect of Income tax expense (benefit); Other income, net; non-operating (gain) loss on investments; debt extinguishment charges; interest expense, net; restructuring and other charges; Medical Device Regulation (“MDR”) fees and other costs; strategic transaction costs; stock-based compensation; depreciation and other amortization; acquisition-related intangible asset amortization; insurance settlement (gain) loss; goodwill impairment charges; and fair value charges on acquired inventory. We also present Adjusted EBITDA and Adjusted EBITDA margin by operating segment, which are subject to the same adjustments. Operating income (loss), adjusted EBITDA and adjusted EBITDA margins at the operating segment level also include allocations of certain central function expenses not directly attributable to either operating segment. Adjusted EBITDA assists our management in comparing operating performance over time because certain items are not normal recurring charges necessary to operate our business, and these items may obscure underlying business trends and make comparisons of long-term performance difficult, difficult as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete restructuring plans and other initiatives that are fundamentally different from our ongoing productivity improvements.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

MD&A298 words changed in this paragraph; it is 32% similar to last year's version.
Net sales increased in Recon by $379.3 million, or 60%, of which $338.1 million was attributable to the Lima and Novastep acquisitions. Recon sales were negatively impacted by a $4.3 million decrease from the discontinuance of certain non-core product lines. Comparable Sales Growth for Recon was driven by approximately 8.2% increase in volume and market share gains and favorable currency translation of 0.3%. Gross profit increased $179.1 million in the year ended December 31, 2024 compared to the prior year period, primarily due to higher net sales due to the Lima Acquisition, and improved operating leverage, offset by an increase of $51.6 million in inventory fair value step-up amortization charges. The increase in inventory step-up charges led to a decrease in Gross profit margin. Selling, general and administrative expense increased by $207.6 $8.3 million over the same period primarily due to increased Strategic transactions costs associated with Lima integration activities, increased an increase in commissions driven by higher sales, a general and administrative expense increase due to the Lima Acquisition, sales and increases in existing business investments to support growth. growth, nearly entirely offset by a decrease in Lima Acquisition integration costs. Research and development expense increased compared to the prior year period due to the Lima Acquisition an increase in new product development projects and increased activities and spending within other our recently acquired businesses in our Recon segment, businesses, which are investing in surgical productivity solutions and computer-assisted surgery technologies. Operating loss increased, primarily due Purchase of royalty interest increased over the same period as we completed strategic purchases to buyout the economic interest in future royalty payments in connection with the termination of certain legacy product development agreements for a Goodwill impairment fixed price of $56.5 million, which will be paid over nine years. We accrued a liability and recognized a $45.8 million charge of $330.0 million, a $48.9 million increase in strategic transaction costs including the deal costs for the Lima Acquisition and integration costs, and an increase in amortization net present value of acquired intangibles and inventory fair value step-up amortization charges, offset by the aforementioned factors driving growth. Adjusted EBITDA increased primarily due to increased gross profit from the Lima Acquisition and improved operating cost leverage. purchases.

Source: Item 7, 10-K 0001420800-26-000012 vs Item 7, 10-K 0001420800-25-000009

Risk Factors160 words changed in this paragraph; it is 61% similar to last year's version.
Our Total total assets reflect substantial intangible assets, primarily Goodwill. The Goodwill results from our acquisitions, representing the excess of cost over the fair value of the net assets we have acquired. We assess annually, or more frequently if an event occurs or circumstances change in the interim that would more likely than not reduce the fair value of the asset below its carrying amount, in order to determine whether there has been impairment in the value of our Goodwill. For In the quarter ended December 31, 2025, we recognized a non-cash Goodwill impairment charge associated with a sustained decrease in our publicly quoted share price and market capitalization relative to the carrying value of our reporting units of $501.0 million as of December 31, 2025 ($157.6 million for the P&R reporting unit and $343.4 million for the Recon reporting unit). Previously, for the quarter ended October 3, 2025, we identified an impairment indicator associated with a sustained decrease in our publicly quoted share price and market capitalization, relative to the carrying value of our reporting units. As a result, we performed an interim quantitative assessment of Goodwill and recognized a non-cash Goodwill impairment charge of $540.8 million as of October 3, 2025 ($222.3 million for the P&R reporting unit and $318.6 million for the Recon reporting unit). Additionally, in connection with our annual assessment for the year ended December 31, 2024, we recognized a non-cash Goodwill impairment charge of $645 $645.0 million ($330 ($315.0 million for the Reconstructive P&R reporting unit and $315 $330.0 million for the Prevention & Recovery Recon reporting unit) as part of our annual Goodwill impairment testing. unit). See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies—Goodwill and Intangible Assets.”

Source: Item 1A, 10-K 0001420800-26-000012 vs Item 1A, 10-K 0001420800-25-000009

Accounting Policies69 words changed in this paragraph; it is 60% similar to last year's version.
A further sustained decline in our share price and market capitalization, future cash flows, end-markets and/or geographic markets could result in additional impairment charges that could materially affect our financial statements in any given year. Actual results could differ from our estimates and projections, which would also affect the assessment of impairment. As of December 31, 2024, after recognition of the $645 million impairment charge, we have Goodwill of $1.7 billion ($925 million for the Reconstructive reporting unit and $768 million for the Prevention and Recovery reporting unit) that is subject to at least annual review for impairment. See Note 9 “Goodwill and Intangible Assets” in the accompanying Notes to Consolidated Financial Statements for the table summarizing the activity in Goodwill.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001420800-26-000012 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001420800-25-000009

Legal Proceedings3 words changed in this paragraph; it is 95% similar to last year's version.
As of December 31, 2024, 2025, the Company had $130.6 $135.1 million of unconditional purchase obligations with suppliers, all of which $124.4 million is expected to be paid by December 31, 2025. 2026.

Source: Item 3, via Note 18 – Commitments and Contingencies, 10-K 0001420800-26-000012 vs Item 3, via Note 18 – Commitments and Contingencies, 10-K 0001420800-25-000009

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of ENOV's Risk Factors and MD&A, 10-K Feb 26, 2026 against 10-K Feb 26, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
We use, and may increasingly use, artificial intelligence (“AI”) and machine‑learning technologies to support aspects of our operations, product development, and business processes. AI technologies are rapidly evolving and may produce unintended, inaccurate, or inconsistent results. If these technologies do not perform as expected, are misused, or are not appropriately governed, our operations, compliance efforts, and reputation could be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedRisk Factors
In addition, changes in political conditions in China and changes in the state of China-U.S. relations, including any tensions relating to potential military conflict between China and Taiwan, are difficult to predict and could adversely affect our business. Furthermore, if other countries, including the United States, become further involved in these or other conflicts, we could face significant adverse effects to our business and financial condition.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedRisk Factors
more dilution than we currently anticipate with respect to our common stock. We can provide no assurance as to the financial stability or viability of the option counterparties.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
For example, as a result of the COVID-19 pandemic, we experienced adverse impacts on sales, as well as material delays and periodic cancellations of elective medical procedures, orthopedic clinics and physical therapy centers operating at reduced levels, and periodic cancellation of sports programs impacting our business. The effect of the COVID-19 pandemic on the global economy resulted in a number of additional challenges for our business, including cost inflation, supply chain challenges such as logistics delays, and healthcare provider staffing shortages, all of which are attributable in some part to the pandemic.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
marking or new products or modified products. If any of these actions were to occur, it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue.
Read it in 10-K Feb 26, 2025 at sec.gov
Show the other 55
RemovedRisk Factors
debarment from government contracts, curtailment of operations in certain jurisdictions, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedRisk Factors
The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the United States, United Kingdom and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia, and Russia has imposed counter-
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedRisk Factors
For Additionally, in connection with our annual assessment for the year ended December 31, 2024, we recognized a non-cash Goodwill impairment charge of $645 $645.0 million ($330 ($315.0 million for the Reconstructive P&R reporting unit and $315 $330.0 million for the Prevention & Recovery Recon reporting unit) as part of our annual Goodwill impairment testing. unit).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Failure to attract, develop, engage, and retain qualified employees, whether as a result of an insufficient number of qualified applicants, difficulty in recruiting new employees, or inadequate resources to train, integrate, and retain qualified employees, could impair our ability to execute our business strategy and could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
The spread or fear of spread of contagious diseases, terrorist activity, man-made or natural disasters, actual or threatened war, political unrest, civil strife and other geopolitical uncertainty could have cause a similar effect on decline in the demand for our products, which may adversely affect our financial condition or our condition, growth strategy. strategy and operating performance.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
If future operating performance at either of our reporting units were to fall significantly below current levels, if competing or alternative technologies emerge, if market conditions for an acquired business decline, or if there is a further sustained decrease in our publicly reported stock price and market capitalization, among other things, we could incur, under current applicable accounting rules, additional non-cash charges to operating earnings for Goodwill impairment, which could be material and may adversely affect our reported earnings. earnings and may impact our ability to designate our Swiss-Franc cross-currency swaps as net investment hedges.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
In addition, such breaches in security could result in litigation, regulatory action and potential liability, including liability under federal or state laws that protect the privacy of personal information, such as HIPAA, as well as the costs and operational consequences of implementing further data protection measures.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Risks relating to contagious diseases, terrorist activity, man-made or natural disasters and war could reduce have adversely impacted, and may, either alone or in combination with other risks, in the demand for our products and future have an adverse effect on our results of operations, financial condition, and business.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by geopolitical uncertainty, political instability, and conflicts, such as the ongoing conflict armed conflicts between Russia and Ukraine. Ukraine and in the Middle East.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws or consumer protection laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Further escalation of geopolitical tensions related to the military conflict, these armed conflicts, including increased trade barriers or restrictions on global trade, which could affect Russia’s allies and other countries, such as China, could result in, among other things, cyberattacks, additional supply disruptions, lower consumer demand and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and supply chain.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Our information technology infrastructure and information are vulnerable to service interruptions, data corruption, cyber-based attacks, or network security breaches, which could result in the disruption of operations or the loss of data confidentiality. breaches.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
For example, the introduction of new tariffs or trade restrictions, such as the tariffs announced by the new U.S. administration in February 2025 restrictions and any retaliatory trade measures could also increase the cost of or impair sourcing flexibility for raw materials and other inputs used in the manufacturing of our products.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedRisk Factors
Any such While to date we have not experienced any material cybersecurity incidents, future attacks and incidents could have a material adverse effect on our business, financial condition, results of operations or liquidity.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
We may elect the one year scope exception provided by the Exchange Act and the applicable SEC rules and regulations concerning business combinations as we did for the Lima acquisition, but we can not cannot avoid the requirements.
Read it in 10-K Feb 26, 2026 at sec.gov
Quiet changesRisk Factors
Energy, commodity, raw material energy, material, labor and other cost inflation has impacted and could continue to impact our results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
We complement our organic growth plans with strategic acquisitions and other investments. Acquisitions can significantly affect our reported results, and so we also report the change in our Net sales between periods both from Existing businesses and Acquired businesses. The change in Net sales due to acquisitions for the years ended December 31, 2025 and 2024 presented in this filing represents the incremental sales in comparison to the portion of the prior period during which we did not own the business. Business acquisitions of a distributor may not add incremental sales in Acquired businesses because we may have had existing business sales through the distributor and the acquisition brings the business into Enovis under a direct sales model and reduces operating costs.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
On October 7, 2025, we completed the sale of our Dr Comfort Footcare Solutions U.S. operations of our P&R segment to Promus Equity Partners in an asset deal, with an effective date of October 4, 2025 (the “Dr Comfort Divestiture”). The sale includes inventory, machinery and equipment, and intangible assets for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million and up to $15 million payable in the future upon the achievement of certain milestones.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
In the year ended December 31, 2025, the Company completed seven transactions for $36.9 million total purchase consideration, including deferred consideration and estimated contingent consideration which included the acquisition of three distributors, two businesses, and two purchases of intellectual property. Of these transactions, three were in the P&R segment and four were in the Recon segment.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(4) MDR and other costs includes (i) $9.8 million for the year ended December 31, 2025 in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.6 million for the year ended December 31, 2025 of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(5) Strategic transaction costs includes: (i) $39.4 million for the year ended December 31, 2025 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $19.5 million for the year ended December 31, 2025 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $1.5 million for the year ended December 31, 2025 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(6) Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture. Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense enhances comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(4) MDR and other costs includes (i) $16.0 million for the year ended December 31, 2024 in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $3.5 million for the year ended December 31, 2024 of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(5) Strategic transaction costs includes: (i) $64.9 million for the year ended December 31, 2024 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $8.8 million for the year ended December 31, 2024 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $4.6 million for the year ended December 31, 2024 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(6) Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture. Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense enhances comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(4) MDR and other costs includes (i) $21.3 million for the year ended December 31, 2023 in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $6.1 million for the year ended December 31, 2023 of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(5) Strategic transaction costs includes: (i) $12.2 million for the year ended December 31, 2023 related to transaction costs and non-recurring integration costs associated with the Lima Acquisition, which includes professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters, (ii) $5.5 million for the year ended December 31, 2023 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $20.6 million for the year ended December 31, 2023 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.gov
AddedMD&A
(6) Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture. Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense enhances comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance.
Read it in 10-K Feb 26, 2026 at sec.gov
RemovedMD&A
We complement our organic growth plans with strategic acquisitions and other investments. Acquisitions can significantly affect our reported results, and so we also report the Net sales on a Comparable Sales basis and present a Comparable Sales Growth rate to provide information on the operating performance of the business. Comparable Sales and Comparable Sales Growth rate are defined in the “Non-GAAP Measures” section below.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
During the year ended December 31, 2022, the Company completed two business acquisitions for aggregate net cash consideration of $50.5 million. In the second quarter of 2022, the Company acquired KICo Knee Innovation Company Pty Limited and subsidiaries, an Australian private company doing business as 360 Med Care, which is a medical device distributor that bundles certain computer-assisted surgery and patient experience enhancement programs to add value to the device supply arrangements with surgeons, hospitals, and insurers. In the third quarter of 2022, the Company acquired a controlling interest in Insight Medical Systems, the flagship product of which is the ARVIS surgical navigation system.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Once the Separation was completed in the second quarter of 2022, we began classifying the results from the fabrication technology business for the comparable periods presented as a discontinued operation in our financial statements. Accordingly, the results of our fabrication technology businesses in our financial statements prior to its spin-off as a separate public company are excluded from continuing operations in the accompanying financials for the year ended December 31, 2022.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Comparable Sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of certain non-core product lines that were divested or discontinued, as applicable, during the periods presented. The acquired businesses include Lima, Novastep, and KICo, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of the divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment. Comparable Sales Growth rate represents the change in Comparable Sales for the current period from Comparable Sales for the prior year period. Comparable Sales and Comparable Sales Growth rate assist our management in evaluating operating performance over time because the impact of significant acquisitions and divestitures or discontinuance of certain non-core product lines subsequent to prior periods may obscure underlying business trends and make the evaluation of period-over-period performance difficult. Comparable Sales and Comparable Sales Growth rate are presented for illustrative purposes only and do not and are not intended to comply with Article 11 of Regulation S-X promulgated by the SEC in respect of proforma financial information, and may differ, including materially, from proforma financial statements presented in accordance therewith.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
(1) Comparable Sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of divested businesses and certain discontinued Recon products lines in conjunction with the Lima Acquisition. The acquired businesses include Lima and Novastep, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of a divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
(1) Comparable Sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of divested businesses and certain discontinued Recon products lines in conjunction with the Lima Acquisition. The acquired businesses include Lima, Novastep, and KiCo, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of a divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Interest expense, net decreased by $4.4 million, primarily due to a reduction in debt balances as a result of the Separation-related debt redemptions at the beginning of the second quarter of 2022, the extinguishment of the outstanding balance of our previous term loan in conjunction with the ESAB investment sale, and interest savings from $7.3 million interest received on the Swiss Franc cross-currency swap agreements.
Read it in 10-K Feb 26, 2025 at sec.gov
RemovedMD&A
Net loss from continuing operations increased $15.6 million during 2023 in comparison to 2022, primarily due to one-time income items in the prior year period, including the Unrealized gain on investment in ESAB Corporation, Gain on cost basis investment, Insurance settlement gain, partially offset by the reduction of debt extinguishment charges and the aforementioned net impact of the Gross profit and Selling, general, and administrative increases as well as the decrease in Interest expense, net and the impact of unfavorable discrete tax items in 2022. Adjusted EBITDA increased due to organic growth. Adjusted
Read it in 10-K Feb 26, 2025 at sec.gov
RewordedMD&A
Restructuring and other charges (2)(3) 20.9 24.3 45.2 5.2 10.0 15.1 MDR and other costs (3) 10.1 9.4 19.5 (3)(4) 5.7 4.7 10.4 Strategic transaction costs (3) 4.3 74.0 78.3 (3)(5) 9.5 50.8 60.4 Stock-based compensation (3) 18.1 11.6 29.7 18.6 14.7 33.3 Depreciation and other amortization 20.6 96.7 117.3 18.8 101.9 120.7 Amortization of acquired intangibles 92.3 73.2 165.5 91.5 82.1 173.6 Goodwill impairment charge 315.0 330.0 645.0 387.8 662.0 1,049.8 Purchase of royalty interest — 45.8 45.8 Inventory step-up (6) — 51.7 51.7 18.1 18.1 Adjusted EBITDA (non-GAAP) $ 159.6 163.1 $ 216.9 239.9 $ 376.5 403.0 Adjusted EBITDA margin (non-GAAP) 14.5 14.3 % 21.5 21.6 % 17.9 %
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net Operating loss from continuing operations increased $773.6 million during 2024 in comparison to 2023, increased, primarily due to a Goodwill impairment charge of $645.0 $330.0 million, a $65.2 $48.9 million increase in strategic transactions transaction costs from including the deal costs for the Lima Acquisition and integration activities, a $37.4 million increase in interest expense, net, a $32.0 million costs, and an increase in amortization of acquired intangibles, and an increase in depreciation intangibles and inventory fair value step-up amortization charges, partially offset by an increase in Gross Profit from the Lima Acquisition. aforementioned factors driving growth.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Selling, general and administrative expense increased $57.4 by $8.3 million during 2023 in comparison to 2022, over the same period primarily due to increased an increase in commissions driven by higher sales, sales and increases in existing business investments to support growth, spending on MDR and other costs, and cost inflation, partially nearly entirely offset by cost reduction initiatives and a net decrease in Strategic transactions Lima Acquisition integration costs.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2024 2025 P&R Recon Total (Dollars in millions) Net loss from continuing operations Loss (GAAP) (1) $ (827.4) (1,183.6) Net Loss margin (GAAP) (52.7) % Loss from discontinued operations, net of taxes 1.9 Income tax expense 4.5 22.3 Other income, expense, net (9.9) 0.4 Interest expense, net 57.1 34.8 Operating loss (GAAP) $ (321.8) (374.1) $ (454.0) (775.7) (750.2) (1,124.2) Operating loss margin (29.3) (32.9) % (45.0) (67.5) % (36.8) (50.0) % Adjusted to add:
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Additionally, Net sales Sales increased during 2023 as compared to 2022 primarily due to an the increase in sales from existing businesses across both of our segments and to segments, partially offset by a lesser extent sales decrease from acquired businesses the divestiture of a hosiery product line in Recon and favorable foreign currency translation. our P&R segment.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Our principal raw materials and components are include foam ethylene vinyl acetate, ethylene-vinyl-acetate copolymer for used in our bracing and vascular products in P&R within P&R, and cobalt chromium alloy, stainless steel cobalt-chromium alloys, stainless-steel alloys, titanium alloy alloys, and ultra high molecular weight ultra-high-molecular-weight polyethylene used in Recon. our Recon products.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 (Dollars in millions) Net sales $1,111.1 $1,009.7 $630.4 $535.5 Gross profit $731.2 $612.3 $433.2 $351.1 Gross profit margin 65.8% 60.6% 68.7% 65.6% Selling, general and administrative expenses $603.5 $595.2 $387.6 $334.0 Research and development expense $83.3 $55.6 $40.3 $27.4 Amortization of acquired intangibles $82.1 $73.2 $40.0 $46.2 Restructuring and other charges $4.7 $12.3 $6.4 $9.4 Purchase of royalty interest $45.8 $— $— Goodwill impairment charge $662.0 $330.0 $— $— Operating loss (GAAP) $(750.2) $(454.0) $(41.0) $(52.9) Operating loss margin (GAAP) (67.5)% (45.0)% (6.5)% (9.9)% Adjusted EBITDA (non-GAAP) $239.9 $216.9 $116.7 $94.7 Adjusted EBITDA margin (non-GAAP) 21.6% 21.5% 18.5% 17.7%
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Additionally, cash flows used in investing activities in 2025, 2024, 2023, and 2022 2023 include $197.4 million, $180.7 million, and $122.2 million, and $105.5 million, respectively, for purchases of property, plant, equipment, and intangibles. intangibles, which represents overall higher capital investments driven by recent acquisitions, including surgical implant instruments that support sales growth in Recon.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Cash flows provided used by financing activities in 2024 2025 include net debt borrowings paydown of $859.2 $36.9 million, partially offset by debt issuance costs of $6.7 million, amounts paid for common stock repurchases of $4.8 million $3.5 million, and amounts paid for deferred consideration payments on acquisitions of $8.8 $6.6 million.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
Net sales in P&R increased $21.2 million, or 2.0%, 2.0% in the year ended December 31, 2024 compared with the prior year period, which was negatively impacted due to solid growth in existing business, partially offset by a $11.1 million decrease from divesting a minor product line. line and unfavorable foreign translation.
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
As a result, the Company recognized a non-cash goodwill impairment charge of $645 $540.8 million ($330 in the quarter ended October 3, 2025 ($222.3 million for the P&R reporting unit and $318.6 million for the Reconstructive reporting unit and $315 million for the Prevention & Recovery reporting unit).
Read it in 10-K Feb 26, 2026 at sec.gov
RewordedMD&A
The Following the Amendment, the Term Loan Facility requires required quarterly principal repayments, which is repayments of $5 million each quarter, million, and matures would mature on April 4, 2027 (the “2024 Term Loan”). 2027.
Read it in 10-K Feb 26, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ENOV/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.